Skip to main content

Change in PDL Status for Antivirals, Oral Drug Class Effective March 7, 2024

Last updated on

Effective March 7, 2024, the Texas Health and Human Services Commission (HHSC) has removed the non-preferred status from the generic valganciclovir tablets on the preferred drug list (PDL).

This change is in response to the shortage of the preferred brand name product Valcyte tablets. The preferred status of Valcyte tablets will not change, so that existing stock may be used.

Providers can now prescribe valganciclovir tablets without requiring a PDL prior authorization, which will allow clients continued access to the necessary medication.

The non-preferred status of the following drugs was removed:

National Drug Code (NDC)Drug Name
00904679604Valganciclovir 450 mg tablet
00904679610Valganciclovir 450 mg tablet
27241015860Valganciclovir 450 mg tablet
31722083260Valganciclovir 450 mg tablet
55111076260Valganciclovir 450 mg tablet
64380015301Valganciclovir 450 mg tablet
65862075360Valganciclovir 450 mg tablet

Note: HHSC is aware of a drug shortage for the brand name Valcyte tablets in the "Antivirals, oral" drug class due to a change in the manufacturer of the product. We received reports of the shortage and change in manufacturers from managed care organizations, which were verified on the American Society of Health-System Pharmacists website.

Email vdp-formulary@hhsc.state.tx.us with any questions.